Rentschler names Benedikt von Braunmuehl as CEO; Catalent grabs David McErlane from Lonza as biologics lead

Benedikt von Braunmuehl has been revealed as Rentschler Biopharma’s new CEO. Meanwhile, Catalent also announced that David McErlane is the CDMO’s new group president of its biologic segment.

Von Braunmuehl, the former CEO of HMNC Brain Health, replaced Frank Mathias, who shifted to Oxford Biomedica in February after seven years at Rentschler. Tuesday marks von Braunmuehl’s first day on the job.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Risk Adjusted Net Present Value: What is the current valuation of Pfizer’s PF-07264660

The revenue for PF-07264660 is expected to reach an annual total of $14 mn by 2039 in the US based off GlobalData’s Expiry Model. The

July 2, 2024

How does SARS-CoV-2 cause lymphopenia when T cells barely express ACE-2 receptors?

Researchers reveal both direct and indirect mechanisms of SARS-CoV-2-induced lymphopenia, highlighting the role of CD147 and alternative viral entry routes into T cells.

July 9, 2024

Overcoming disruptions in the pharmaceutical supply chain – Pharmaceutical Technology

On 5 May 2023, the director-general of the World Health Organization declared an official end to Covid-19 as a global health emergency. As many of

September 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.